KalVista Pharmaceuticals

42 articles with KalVista Pharmaceuticals

• KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

  9/26/2019

  KalVista Pharmaceuticals, Inc. announced that it will present at the Cantor Global Healthcare Conference on Thursday, October 3, 2019, at 10:05 a.m. ET in New York, NY.

• KalVista Pharmaceuticals Reports Fiscal First Quarter Results of 2019

  9/9/2019

  KalVista Pharmaceuticals, Inc. provided an operational update and released financial results for the fiscal first quarter ended July 31, 2019.

• KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results - July 15, 2019

  7/15/2019

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors provided an operational update and released financial results for the fiscal year ended April 30, 2019.

•  KalVista Pharmaceuticals Announces Changes to Board of Directors

  7/1/2019

  KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Martin Edwards has been appointed and Richard H. Aldrich is resigning from the Company’s Board of Directors.

• KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology

  6/4/2019

  KVD900 Demonstrates Rapid and Nearly Complete Suppression of Plasma Kallikrein Activity in a Phase 1 Study

• KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference - May 30, 2019

  5/30/2019

  KalVista Pharmaceuticals, Inc. announced that it will present at the Jefferies Healthcare Conference on Thursday, June 6, 2019, at 4:00 p.m. ET in New York, NY.

• KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop

  5/28/2019

  KVD900 Phase 1 Data Show Rapid Suppression of Plasma Kallikrein Activity and is Well Tolerated for Potential Use as On-Demand Treatment for HAE

• KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences

  5/20/2019

  Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented

• KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019

  4/30/2019

  Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054 Prevent and Reverse VEGF-Induced Retinal Edema in Mice

• KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

  4/22/2019

  KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that Daniel Soland has been appointed to its Board of Directors effective immediately.

• KalVista Pharmaceuticals to Present at Needham Healthcare Conference

  4/3/2019

  KalVista Pharmaceuticals, Inc. announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, at 2:10 p.m. ET in New York, NY.

• KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer

  3/27/2019

  KalVista Pharmaceuticals, Inc. announced the promotion of Ben Palleiko to Chief Business Officer in addition to his current role as Chief Financial Officer, effective immediately.

• KalVista Pharmaceuticals Reports Fiscal Third Quarter Results - March 14, 2019

  3/14/2019

  KalVista Pharmaceuticals, Inc. provided an operational update and released financial results for the fiscal third quarter ended January 31, 2019.

• KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019

  2/25/2019

  KalVista Pharmaceuticals, Inc. announced data from a poster presentation given Saturday, February 23, at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 in San Francisco, CA.

• KalVista Pharmaceuticals Appoints Brian J. G. Pereira, MD to Board of Directors

  2/1/2019

  KalVista Pharmaceuticals, Inc. announced that Brian Pereira has been appointed to its Board of Directors effective February 1, 2019.

• KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans

  1/4/2019

  KVD900 Phase 2 HAE Trial Data Expected in 2019

• KalVista Pharmaceuticals Reports Fiscal Second Quarter 2018 Results

  12/14/2018

  KVD900 Enlarged Phase 2 Trial on Track for Potential On-Demand Treatment of Attacks in Patients with Hereditary Angioedema

• KalVista Pharmaceuticals Provides Clinical Update on KVD900

  11/12/2018

  Enlarged Phase 2 Study to Begin in 2018 for Potential Acute Treatment of Hereditary Angioedema; Data Expected in Late 2019

• KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

  11/6/2018

  KalVista Pharmaceuticals, Inc. today announced that it will present a corporate overview at the following upcoming investor conferences.

• KalVista Pharmaceuticals to Present at 2018 Cantor Global Healthcare Conference

  9/25/2018

  KalVista Pharmaceuticals, Inc. today announced that it will present at the Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 8:00 a.m. ET in New York, NY.